No way to sticky questions here, right? Just some of my

New Post Public Reply Private Reply Replies (1) Message Board
docj
512
No way to sticky questions here, right? Just some of my questions and I am sure they could be worded better by someone with talent for writing vs complaining.

1) Did we get an acknowledgement from the SEC they rec'd the S-1?
- Have we rec'd a response yet and if so what follow up information did they request and has that info been sent?

2) What resource is available to look up the number of shareholders in Generex stock?

3) Has there been an employee benefit plan set up such that employees of Generex can buy stock in a legally compliant manner?

4) Bear with me on this as I have to relay information before I can get to the question at the end.

Generex on 11/26 released the first shareholder alert "regarding recent trading activity" in the companies stock.

However, back on July 25 during the CC you took a calls regarding the selling of restricted shares during which the following discussions took place:

Joe Moscato: I have no idea how anyone could sell restricted shares.

Jacob Kaufman: You know who owns them and you know how legally they are locked in. so if you are saying it’s impossible, then it’s impossible.

Joe Moscato: On restricted shares it’s impossible. As far as the –

Earlier during the CC you took this call:

Richard Proctor: I’m watching stock price go up and then I see it get hit with 50,000, 60,000 shares and I’m wondering if those are people that are unloading cheaper shares just to make the profit.

Joe Moscato: No, not at all. There’s nobody that has any shares from any notes. No one has gotten any shares from any notes. Any shares that potentially could come in any market, and again I haven’t given out a lot of shares to anybody. So any shares that could come in the market would be restricted. I have no registration statement approved. So I don’t believe it would be any shares coming into the market of any kind of significance for a long time. I haven’t given anybody any.

Richard Proctor: It’s almost like a dream; too good to be true. I’ll hear the story and I’m looking for where’s the crack in this because it can’t be – there’s nobody out there that’s going to put the shareholders first. This has got to be a thing where if you look on the other side there’s the catch. But I don’t see it and thank you. That’s all I got to say.

Joe Moscato: Don’t take my word for it. I’ll instruct our TA _____ [01:17:22] you want to call them and ask them if anybody has ever –

Richard Proctor: I’ll take your word for it Joe. You seem to be that kind of guy. So I’m just going to go with my gut –

Joe Moscato: Appreciate that.

Generex Investor Call 07/25/2019


Page 24 of 29
Richard Proctor: More cash, I’ll buy more stock.

Unidentified male: Joe just as clarification on this. This morning there was some – there are some instruments out there that are convertible and just this morning there were some conversions. They like what’s going on and they want to participate.

Joe Moscato: But they’re restricted shares. I just said free trade shares. Restricted shares are completely different than free trade shares.

Unidentified male: There is a mechanism for them to go free trading on it.

Richard Proctor: The game is played the way it’s played; so you got to bet against it. So that’s good. I pretty much got what I came to hear _____ [01:18:17] other than I’m pleased with what you’re doing and I hope this thing works out for everybody. The last question I asked in a conference call was to Anna _____ [01:18:27], you know? I’m good with what’s going on and I’m hoping to see a big change here.

Joe Moscato: All I can say is I’m in New York and like I said, if someone tried to convert something again, it’s only going to be restricted shares because there is no registration. Again I appreciate the call, thank you very much.


Joe, please explain these two discussions and clarify how, if at all the CM and Venoto selling applies.


5) Please list, specifically, what items remain to be completed for Generex's NAZ up application to be approved so the up listing can be completed? What steps are needed to achieve those items being completed? What is the expected time frame?

6) Have you contacted all parties who own Generex shares as a result of what has occurred with CM and Veneto and have any of those parties sold shares? Have these parties assured you they will not sell and are there any new agreements in place covering this possibility.

7) If the dividend is to be distributed, when? How many shares will there be after the dividend is provided? The parties who own shares as part of their purchase agreements are still not eligible to receive the dividend, correct?

8) Investors are concerned they may have purchased shares from CM or Veneto that may not be eligible for the dividend. Is this an issue?

9) Please explain the steps needed to take NGIO public and which exchange do you anticipate the company shares trading and when? Where are we at in the process? Recently some have brought up the possibility a separate S-1 will need to be filed. Please clarify. Where will the operating funds for NGIO come?

10) Can you give an update on the AE37/Keytruda study?

11) What law firm is handling the CM matter?

12) What is Dr Kiran Patel's current association with Generex? Where do you see his involvement moving forward? Say 6 months from now.

13) I am sure he will provide not a lot of detail on CM and Veneto but I would want to know if we are having back and forth discussions and if Generex has filed any legal documents as of yet.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TORRAS Stands Tall with iPhone 18 Pro Cases

Updated Category News Views 191

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 214

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 135

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 295

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 270

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
DigitalXForce Booms with 514% Growth and Major Backing

Updated Category News Views 282

Massive Growth and Strategic Investment in DigitalXForce Now here’s a company that’s shaking things up—DigitalXForce. Right on the back of a staggering 514% growth, they’ve corralled a strategic investment from Arsenal Growth Equity. If you blink, you might miss just how fast they’re sprinting through the tech landscape. Institutional Support Backing the...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 92

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 69

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 143

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 86

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Oral Semaglutide Curbs Heavy Drinking: CU Study Insights

Updated Category News Views 12

New Frontiers in Tackling Alcohol Use Disorder Diabetes meds aren't just boxing in sugar levels; they're taking swings at alcohol cravings, too. The University of Colorado Anschutz threw their hat in the ring with a study that put oral semaglutide—usually in the diabetes and weight loss circuit—to a different test. Turns out, it's packing a punch against heavy...

Continue Reading
Julie Van Kleeck Strengthens Leadership at Paragon Space

Updated Category News Views 121

Julie Van Kleeck Joins Paragon Space Development Corporation Board Paragon Space Development Corporation (Paragon) proudly announces the appointment of Julie Van Kleeck to its Board of Directors. With a remarkable background in the space technology sector, Julie is set to enhance Paragon's mission with her extensive market insights and solid operational experience. Rich...

Continue Reading
Exploring Advanced Techniques for Fracture Healing in Orthopaedics

Updated Category News Views 302

Micromotion Nailing for Enhanced Fracture Healing OrthoXel is thrilled to announce an important presentation by Dr. Hannah Dailey, Co-Founder and Chief Scientific Officer, focusing on the innovative technique of micromotion nailing aimed at accelerating fracture healing. This presentation will be highlighted at an esteemed meeting gathering leading experts in the field of...

Continue Reading
Resilient Job Market Gains Amid Signs of Slowing Growth Ahead

Updated Category News Views 191

Overview of Recent Labor Market Trends The US economy has shown unexpected strength, adding more jobs than anticipated recently, instilling fresh optimism regarding the labor market's near-term stability. With political changes on the horizon, the economy's performance under the new administration remains a topic of interest. Nonetheless, we can assert that the incoming...

Continue Reading
MD Hyperbaric Expands Presence in Key U.S. Markets

Updated Category News Views 6

Expanding the Oxygen Therapy Frontier When you're talking about healing that's both ancient and cutting-edge, hyperbaric oxygen therapy (HBOT) kind of steals the show. MD Hyperbaric, calling the shots since 2021, is breaking new ground in San Antonio, Las Vegas, and Rochester. Why This Matters HBOT isn't just another fancy healthcare fad. We're seeing a real push toward...

Continue Reading